Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others. Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet...
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.031 | -5.3726169844 | 0.577 | 0.5923 | 0.52 | 52347 | 0.53707444 | CS |
| 4 | -0.114 | -17.2727272727 | 0.66 | 0.665 | 0.51 | 78487 | 0.57612373 | CS |
| 12 | -2.554 | -82.3870967742 | 3.1 | 4.25 | 0.5 | 233481 | 0.83581207 | CS |
| 26 | -7.434 | -93.1578947368 | 7.98 | 9.6 | 0.5 | 560286 | 5.7450334 | CS |
| 52 | -9.529 | -94.5806451613 | 10.075 | 21.5 | 0.5 | 926219 | 9.78935275 | CS |
| 156 | -51.454 | -98.95 | 52 | 53 | 0.5 | 1374411 | 22.30086852 | CS |
| 260 | -87.954 | -99.3830508475 | 88.5 | 124.5 | 0.5 | 1828047 | 40.74905114 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
